H2SITE
17.11.2022 09:01:40 CET | Business Wire | Press release
Hydrogen takes a new step as a for the energy transition thanks to H2SITE, which has launched the world's first membrane manufacturing plant to obtain hydrogen from ammonia or methanol, and separate hydrogen from low concentration gas blends. The new facility will industrialize the production of membranes, the technological heart of H2SITE, used in the construction of hydrogen production reactors and separators. Similar membranes made of palladium alloys had been so far very costly, fragile, and difficult to manufacture and scale. H2SITE has managed to overcome these obstacles.
Located in Loiu (Biscay Region, Spain), the new H2SITE plant has a production capacity of tens of thousands of membranes per year. For its construction, H2SITE has invested more than 3 million euros, which it plans to double in the coming years to increase production capacity.
“Once the first production line has been validated, our objective is to significantly increase the capacity of the plant, vertically integrate the manufacturing process of the membrane and build new plants to tackle new markets,” according to Andrés Galnares, CEO of H2SITE. "Our objective is to significantly increase the number of membranes produced each year for the next 3 years, which entails continuing to invest in production assets similar to those we have already installed and increasing their level of automation to further reduce our costs.”
In 2022, H2SITE has booked orders of more than 5 million euros. Galnares assures that the goal is to double that figure over the next year, reaching a workforce of more than 50 professionals.
Asier Rufino, CEO of TECNALIA Ventures and President of H2SITE, states that "at TECNALIA we have been working for 20 years on the development and scaling up of hydrogen technologies its entire value chain: production, distribution, transport, storage and end uses. Together with the Technical University of Eindhoven (TU/e), the technology H2SITE leverages on was created. Today, H2SITE has scaled the process, has industrialized it, and is managing to reduce its cost to be able to develop new use cases”.
“This plant reflects the success of more than 10 years of collaboration initiated by TECNALIA and TU/e and supported by the Public Administration. H2SITE brings it to a new level with the industrialization of a disruptive process thanks to the help of investors who believe that technology is a critical enabler for the energy transition, such as ENGIE New Ventures, Breakthrough Energy Ventures, EQUINOR Ventures and institutional investors from the Basque Country Capital Riesgo País Vasco and Seed Capital Bizkaia. Along with the team that we have created, we cannot wish for better partners at this time," says Galnares.
The membrane separators and reactors will help provide hydrogen with high purity and limited cost, with focus on hard to abate industry sectors and heavy land and maritime mobility.
H2SITE is currently hiring in Europe. To learn more, follow H2SITE on LinkedIn.
About H2SITE
H2SITE was created in 2019 and has an exclusive technology of reactors separators for the conversion of different raw materials into hydrogen, among which are ammonia, methanol or synthetic gas, in addition to the separation of hydrogen from gaseous mixtures in low concentration.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome12.10.2026 08:00:00 CEST | Press release
Final analysis of 109 patients from 18 German centres demonstrates durable treatment outcomes in routine clinical practice1Median time-to-next-treatment(TTNT), the study's primary endpoint, was 14.9 months, alongside a 62.4% best overall response rate, 20.2-month overall median progression-free survival and improved quality of life from baseline reported in routine care1Exploratory analyses show meaningful responses in clinically relevant subgroups, including large cell transformation, folliculotropic mycosis fungoides and mogamulizumab-associated rash status, supporting individualised treatment for patients with mycosis fungoides and Sézary syndrome1 Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous
Megaport Expands Global Automated Infrastructure Platform Into Portugal12.10.2026 08:00:00 CEST | Press release
Megaport’s expansion to Portugal unlocks access to compute, network, and storage services for the local and global markets. Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more than 1,200 enabled data centers worldwide. This launch gives enterprises, MSPs, and carriers private, high-performance compute, network, and storage, as well as on-demand regional interconnection with scalable bandwidth. With Portugal’s data center market projected to reach US$3.09 billion by 2030 as well as Lisbon’s proximity to major submarine cable landings, the strengthening global connectivity hub is a natural
Filippo Fagnani from Quanta System Receives the EAU Award for Significant Contribution to Endourology at ICE 202610.10.2026 18:09:00 CEST | Press release
Filippo Fagnani, Marketing & Scientific Director of Quanta System’s Surgical Division, has been honoured with the Award for Significant Contribution to Endourology at ICE26, the International Conference on Endourology organised by the EAU Endourology Section. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010101303/en/ Filippo Fagnani receiving the prize with Olivier Traxer and Professor Bhaskar Somani. The recognition celebrates more than two decades of professional commitment to laser technology and a career built around a clear ambition: to translate the needs of urologists into increasingly precise, flexible and useful technologies, with the ultimate goal of supporting patient safety and better surgical outcomes. “I have always believed that technology should make the surgeon’s work more precise, more flexible and, most importantly, safer for the patient. My goal has never been to develop technology for its own sake,
Emdoor Information Marks 18 Years of Rugged Computing Excellence with Vertically Integrated Capabilities10.10.2026 12:30:00 CEST | Press release
As industrial automation, smart manufacturing, and field operations increasingly depend on mission-critical mobile computing, global demand for reliable rugged tablets, rugged laptops, and rugged handhelds continues to accelerate. Emdoor Information, a publicly listed company on China’s A-share main board since 2023 and an 18-year veteran in rugged computing, has established itself as a rugged computing solutions provider for industrial customers worldwide. Founded in 2008, the company delivers sustained growth, world-class manufacturing, resilient supply chains, full-stack R&D, and comprehensive lifecycle services. Its rugged computing products and industrial customers now span North America, Latin America, Europe, and Asia-Pacific, serving sectors such as public utilities, intelligent manufacturing, warehouse management, transportation, energy industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261010564561/en/ Rugged
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom